Cargando…

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

BACKGROUND: Therapeutic drug monitoring (TDM) aid therapeutic decision making in patients with inflammatory bowel disease (IBD) who lose response to anti-TNF therapy. Our aim was to evaluate the frequency and predictive factors of loss of response (LOR) to adalimumab using TDM in IBD patients. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonczi, Lorant, Kurti, Zsuzsanna, Rutka, Mariann, Vegh, Zsuzsanna, Farkas, Klaudia, Lovasz, Barbara D., Golovics, Petra A., Gecse, Krisztina B., Szalay, Balazs, Molnar, Tamas, Lakatos, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549364/ https://www.ncbi.nlm.nih.gov/pubmed/28789636 http://dx.doi.org/10.1186/s12876-017-0654-1

Ejemplares similares

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database
por: Kurti, Zsuzsanna, et al.
Publicado: (2018)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
por: Lontai, Livia, et al.
Publicado: (2023)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

The Use of Complementary and Alternative Medicine Is Less Frequent in Patients with Inflammatory Bowel Disease Than in Patients with Other Chronic Gastrointestinal Disorders
por: Fábián, Anna, et al.
Publicado: (2018)

Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
por: Resál, Tamás, et al.
Publicado: (2021)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
por: Dulic, Sonja, et al.
Publicado: (2020)

The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
por: Farkas, Klaudia, et al.
Publicado: (2021)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center
por: Szántó, Kata, et al.
Publicado: (2018)

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states
por: Rencz, Fanni, et al.
Publicado: (2019)

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
por: Resál, Tamás, et al.
Publicado: (2023)

Endoscopic management of complications of self-expandable metal stents for treatment of malignant esophageal stenosis and tracheoesophageal fistulas
por: Bor, Renáta, et al.
Publicado: (2017)

Rectal Tumour Staging with Endorectal Ultrasound: Is There Any Difference between Western and Eastern European Countries?
por: Fábián, Anna, et al.
Publicado: (2016)

How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system
por: Bálint, Anita, et al.
Publicado: (2018)

Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum
por: Rutka, Mariann, et al.
Publicado: (2016)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
por: Szántó, Kata Judit, et al.
Publicado: (2021)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
por: Bacsur, Péter, et al.
Publicado: (2023)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Risk Factors and Interpretation of Inconclusive Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology in the Diagnosis of Solid Pancreatic Lesions
por: Bor, Renáta, et al.
Publicado: (2023)

Comparison of therapeutic efficacy and treatment costs of self-expandable metal stents and plastic stents for management of malignant biliary obstruction
por: Bor, Renáta, et al.
Publicado: (2023)

Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
por: Resál, Tamás, et al.
Publicado: (2021)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Effect of COVID-19 pandemic on workflows and infection prevention strategies of endoscopy units in Hungary: a cross-sectional survey
por: Bor, Renáta, et al.
Publicado: (2021)

Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells
por: Jenei, Viktória, et al.
Publicado: (2022)

Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia
por: Madar, László, et al.
Publicado: (2022)

Analysis of risk factors - especially different types of plexitis - for postoperative relapse in Crohn’s disease
por: Milassin, Ágnes, et al.
Publicado: (2017)

Efficacy of the population-based pilot colorectal cancer screening, Csongrád county, Hungary, 2015
por: RUTKA, Mariann, et al.
Publicado: (2020)

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice
por: Calvo Moya, Marta, et al.
Publicado: (2023)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Enteroscopy in small-bowel Crohn’s disease (CD): hypes and hopes
por: Gecse, Krisztina B., et al.
Publicado: (2014)

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Prospective comparison of slow-pull and standard suction techniques of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of solid pancreatic cancer
por: Bor, Renáta, et al.
Publicado: (2019)

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
por: Bacsur, Péter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6boc1d8bdlcml7saknkga366fp